The BCL-6 gene is the locus where breakpoints involving chromosomal translocations in 30-40 percent of diffuse large cell lymphoma and 6-11 percent of follicular lymphoma are found. These translocations lead to dysregulated expression of BCL-6 by juxtaposing heterologous promoters upstream of BCL-6 coding sequences. The product of the BCL-6 gene is a POZ/Zinc-finger protein that is expressed in germinal center B cells. Recent evidence suggests that BCL-6 can act as a sequence-specific repressor of transcription. However, the target genes for this activity have not yet been identified. Interestingly, the optimal binding site for BCL-6 defined in vitro shares striking homology to the GAS sites that are the target sequences for the cytokine-induced STAT (Signal Transducers and Activators of Transcription) signaling molecules. EMSA reveal that BCL-6 can bind to the binding site of the IL-4 activated protein, Stat6. Using reporter constructs with Stat6 binding sites we find that BCL-6 can repress IL-4 induced transcription. In addition, this repression is dependent on the POZ/repressor domain located at the amino terminus of BCL-6. Therefore, genes regulated by STAT binding sites may be one class of targets for BCL-6 mediated transcriptional repression. Germinal center B cells are exposed to an array of cytokines during an immune response. The repressor activity of BCL-6 may perform an important role in regulating the responsiveness of these B cells to cytokines and thereby act to modulate B cell differentiation. To determine the importance of BCL-6/STAT interactions we propose to: 1) Determine if BCL-6 represses the ability of different STAT molecules to activate transcription; (2) Explore the mechanism by which BCL-6 represses STAT function; 3) Determine if mice lacking BCL-6 have altered responses to cytokines; 4) Determine if BCL-6 transgenic mice have altered responses to cytokines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA072699-03
Application #
6203404
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Harris, Miera B; Mostecki, Justin; Rothman, Paul B (2005) Repression of an interleukin-4-responsive promoter requires cooperative BCL-6 function. J Biol Chem 280:13114-21
Pasqualucci, Laura; Migliazza, Anna; Basso, Katia et al. (2003) Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101:2914-23
Sayers, Thomas J; Brooks, Alan D; Koh, Crystal Y et al. (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102:303-10
Pandolfi, P P (1998) Knocking in and out genes and trans genes: the use of the engineered mouse to study normal and aberrant hemopoiesis. Semin Hematol 35:136-48